Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GALR3 | O60755 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.30 |
| ▸ | GLRB | P48167 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3048199 | 0.75 | GLRA3 (0.33) | GLRA3GLRB | |
| SCHEMBL5004221 | 0.67 | SMN1; SMN2 (0.40) | MEN1GALR3HTTKMT2ASMN1; SMN2 | |
| SCHEMBL3016189 | 0.67 | TDP1 (0.35) | MEN1GALR3HTTKMT2ASMN1; SMN2 | |
| SCHEMBL12207813 | 0.64 | ALDH1A1 (0.41) | MEN1GALR3HTTKMT2ASMN1; SMN2 | |
| SCHEMBL10813783 | 0.61 | TSHR (0.54) | MEN1GALR3HTTKMT2ASMN1; SMN2 | |
| SCHEMBL4924664 | 0.61 | SMN1; SMN2 (0.47) | MEN1GALR3HTTKMT2ASMN1; SMN2 | |
| SCHEMBL397236 | 0.60 | SMN1; SMN2 (0.61) | MEN1GALR3HTTKMT2ASMN1; SMN2 | |
| SCHEMBL2437573 | 0.60 | AR (0.35) | HTTSMN1; SMN2ALDH1A1TSHRTDP1 | |
| SCHEMBL5587447 | 0.60 | MEN1 (0.50) | MEN1GALR3HTTKMT2ASMN1; SMN2 | |
| SCHEMBL8768833 | 0.58 | PKM (0.44) | MEN1GALR3HTTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | claimed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | CNR2, CNR1, SLC18A2 | MEN1 1636/4885GALR3 212/4885HTT 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.